R
Rapport Therapeutics Inc. D
D
RAPP
38.610
USD
1.92
(5.23%)
Market Open
Volume
8,970
EPS
-2
Div Yield
-
P/E
-14
Market Cap
1,845,285,529
Title: Rapport Therapeutics Inc.
Sector: Healthcare
Industry: Biotechnology
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.